The company has quietly emerged as the key player to watch in an area that has seen several setbacks of late.
The usual story of positive data and clinical failure influencing company stock performance was given added interest in the second quarter with price fixing allegations…
Yet another project brought in through business development fails, exposing Sumitomo’s limited pipeline.
Payment of an overdue $120m Astrazeneca milestone, plus two other obligations, has been met through a loan facility with undisclosed terms.
The group follows licensing deals with Dainippon and Roivant with a pivotal study win.
What was up is now down as smaller biotech stocks deal with clinical trial failure and acquisitions.
Roche awaits a high-risk, high-reward readout in autism, while for Ocular Therapeutix placebo ought to be easier to beat than active control.
The heavily promoted company’s cell therapy fails a key study in ischaemic stroke.
Some of the big small-cap fallers, meanwhile, have been subject of M&A activity. Is this a sign of things to come in 2019?